Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dry Eye Syndrome
ArGentis' licenses second treatment for dry eye syndrome
February 14th, 2007
ArGentis, LLC, a Memphis, Tennessee-based specialty biopharmaceutical company, has licensed a second treatment for dry eye syndrome (DES) developed by researchers at the Southern College of Optometry (SCO) in Memphis. The licensed patent application covers the use of transdermal progesterone in the treatment of DES, a condition that affects at least 20 million people in the U.S. and over 100 million people worldwide. The license agreement for this new DES treatment follows arGentis' earlier licensure of intellectual property covering the use of transdermal testosterone in the treatment of DES, which would be prescribed in menopausal women. Approximately 30% of...
Source: Medical Patent Law Weekly (2007-02-14)
|
